ATE342967T1 - Anti-invasive and anti-angiogene urokinase fragmente und deren verwendung - Google Patents

Anti-invasive and anti-angiogene urokinase fragmente und deren verwendung

Info

Publication number
ATE342967T1
ATE342967T1 AT98937112T AT98937112T ATE342967T1 AT E342967 T1 ATE342967 T1 AT E342967T1 AT 98937112 T AT98937112 T AT 98937112T AT 98937112 T AT98937112 T AT 98937112T AT E342967 T1 ATE342967 T1 AT E342967T1
Authority
AT
Austria
Prior art keywords
angiogenesis
pro
glu
ser
variant
Prior art date
Application number
AT98937112T
Other languages
English (en)
Inventor
Terence R Jones
Andrew P Mazar
Original Assignee
Angstrom Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Angstrom Pharmaceuticals Inc filed Critical Angstrom Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE342967T1 publication Critical patent/ATE342967T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6462—Plasminogen activators u-Plasminogen activator (3.4.21.73), i.e. urokinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21073—Serine endopeptidases (3.4.21) u-Plasminogen activator (3.4.21.73), i.e. urokinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Materials For Medical Uses (AREA)
AT98937112T 1997-07-25 1998-07-24 Anti-invasive and anti-angiogene urokinase fragmente und deren verwendung ATE342967T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/900,327 US5994309A (en) 1997-07-25 1997-07-25 Anti-invasive and anti-angiogenic compositions and methods

Publications (1)

Publication Number Publication Date
ATE342967T1 true ATE342967T1 (de) 2006-11-15

Family

ID=25412335

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98937112T ATE342967T1 (de) 1997-07-25 1998-07-24 Anti-invasive and anti-angiogene urokinase fragmente und deren verwendung

Country Status (11)

Country Link
US (5) US5994309A (de)
EP (1) EP0950096B1 (de)
AT (1) ATE342967T1 (de)
AU (1) AU752205B2 (de)
CA (1) CA2269772A1 (de)
CY (1) CY1107051T1 (de)
DE (1) DE69836199T2 (de)
DK (1) DK0950096T3 (de)
ES (1) ES2275309T3 (de)
PT (1) PT950096E (de)
WO (1) WO1999005263A1 (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030144570A1 (en) * 1999-11-12 2003-07-31 Angiotech Pharmaceuticals, Inc. Compositions and methods for treating disease utilizing a combination of radioactive therapy and cell-cycle inhibitors
US7361643B2 (en) 2000-02-09 2008-04-22 University Of Puerto Rico Methods for inhibiting angiogenesis
AU2001243515A1 (en) * 2000-03-08 2001-09-17 Rhode Island Hospital, A Lifespan Partner Combination drug therapy
AU2001253479A1 (en) 2000-04-13 2001-10-30 Sts Biopolymers, Inc. Targeted therapeutic agent release devices and methods of making and using the same
AU2002223316A1 (en) * 2000-11-07 2002-05-21 University Of Victoria Innovation And Development Corporation Detection of proteases and screening for protease inhibitors
ATE308335T1 (de) 2001-02-05 2005-11-15 Innoventus Project Ab Histidine-rich glycoprotein (hrgp) zur hemmung der angiogenese
US6589997B2 (en) * 2001-06-29 2003-07-08 North Shore-Long Island Jewish Health System Small-molecule modulators of hepatocyte growth factor/scatter factor activities
AU2003225008A1 (en) * 2002-04-15 2003-11-03 American National Red Cross Plasma protein-binding ligands
NZ540889A (en) * 2002-11-25 2008-09-26 Attenuon Llc Peptides which inhibit angiogenesis, cell migration, cell invasion and cell proliferation, compositions and uses thereof
IL156566A0 (en) * 2003-06-19 2004-01-04 Hadasit Med Res Service Urokinase plasminogen activator derived octapeptide in the treatment of multiple sclerosis
WO2005002526A2 (en) * 2003-07-01 2005-01-13 President And Fellows Of Harvard College Method and compositions for treatment of viral infections
EP2335694B1 (de) 2003-09-15 2018-06-13 NanoPharmaceuticals LLC Thyroidhormon-analoga und deren verwendung
US9198887B2 (en) 2003-09-15 2015-12-01 Nanopharmaceuticals Llc Thyroid hormone analogs and methods of use
US8071134B2 (en) * 2003-09-15 2011-12-06 Ordway Research Institute, Inc. Thyroid hormone analogs and methods of use
US8668926B1 (en) 2003-09-15 2014-03-11 Shaker A. Mousa Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof
US20050101582A1 (en) 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US7993634B2 (en) 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US9498457B2 (en) 2004-04-30 2016-11-22 Allergan, Inc. Hypotensive prostamide-containing biodegradable intraocular implants and related implants
US8722097B2 (en) 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
TWI366459B (en) * 2004-09-28 2012-06-21 Ind Tech Res Inst Novel hydrophilic analogs of 4,8-dihydrobenzodithiophene-4,8-diones as anticancer agents
US9498536B2 (en) 2005-09-15 2016-11-22 Nanopharmaceuticals Llc Method and composition of thyroid hormone analogues and nanoformulations thereof for treating anti-inflammatory disorders
US10130686B2 (en) 2005-09-15 2018-11-20 Nanopharmaceuticals Llc Method and composition of thyroid hormone analogues and nanoformulations thereof for treating inflammatory disorders
WO2007035612A2 (en) 2005-09-16 2007-03-29 Ordway Research Institute, Inc. Polyphenol conjugates as rgd-binding compounds and methods of use
US20070134739A1 (en) * 2005-12-12 2007-06-14 Gyros Patent Ab Microfluidic assays and microfluidic devices
US8524663B2 (en) * 2006-03-03 2013-09-03 New York University Method for site-specific polyvalent display on polymers
EP1840570A1 (de) * 2006-03-31 2007-10-03 F. Hoffmann-La Roche Ag Tumormodell unter Verwendung von grünem Fluoreszenzprotein
US8039010B2 (en) 2006-11-03 2011-10-18 Allergan, Inc. Sustained release intraocular drug delivery systems comprising a water soluble therapeutic agent and a release modifier
US8969415B2 (en) 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
EP2120913B1 (de) * 2006-12-22 2015-01-21 NanoPharmaceuticals LLC Nanopartikel- und polymerformulierungen für schilddrüsenhormonanaloga, -antagonisten und -formulierungen sowie verwendungen damit
US8481273B2 (en) * 2008-06-20 2013-07-09 University Of Delaware Perlecan fragments as biomarkers of bone stromal lysis
US20100159021A1 (en) * 2008-12-23 2010-06-24 Paul Davis Small Molecule Ligands of the Integrin RGD Recognition Site and Methods of Use
AU2010221168A1 (en) * 2009-03-06 2011-10-06 Angstrom Pharmaceuticals, Inc. Compositions and methods for modulation of cell migration
US9180107B2 (en) * 2009-03-31 2015-11-10 Nanopharmaceuticals Llc Combination treatment of cancer with cetuximab and tetrac
CA2765792C (en) * 2009-06-17 2017-03-28 Ordway Research Institute, Inc. Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof
KR101911960B1 (ko) 2010-01-22 2018-10-25 알러간, 인코포레이티드 전방내 서방성 치료제 이식물
US8697629B2 (en) * 2010-03-05 2014-04-15 Angstrom Pharmaceuticals, Inc. Modulation of intracellular signaling
US8802240B2 (en) 2011-01-06 2014-08-12 Nanopharmaceuticals Llc Uses of formulations of thyroid hormone analogs and nanoparticulate forms thereof to increase chemosensitivity and radiosensitivity in tumor or cancer cells
WO2015074050A1 (en) 2013-11-18 2015-05-21 Nanopharmaceuticals Llc Methods for screening patients for resistance to angioinhibition, treatment and prophylaxis thereof
US20190381127A1 (en) 2016-02-02 2019-12-19 Splash Pharmaceuticals, Inc. Combination therapy with a6, chemotherapeutic agents, radiation therapy, or a combination thereof for the treatment of cancer
US10201616B2 (en) 2016-06-07 2019-02-12 Nanopharmaceuticals, Llc Non-cleavable polymer conjugated with αVβ3 integrin thyroid antagonists
CN107722115A (zh) * 2017-11-29 2018-02-23 吉林大学 一种新型重组蜂毒多肽及其制备方法和应用
US11351137B2 (en) 2018-04-11 2022-06-07 Nanopharmaceuticals Llc Composition and method for dual targeting in treatment of neuroendocrine tumors
US10328043B1 (en) 2018-04-11 2019-06-25 Nanopharmaceuticals, Llc. Composition and method for dual targeting in treatment of neuroendocrine tumors
CN109180822B (zh) * 2018-11-14 2021-08-10 上海交通大学 一种猪链球菌b细胞优势表位串联疫苗及其制备方法
CN111603567A (zh) 2019-02-22 2020-09-01 博瑞生物医药（苏州）股份有限公司 Cd44靶向多臂偶联物
US10961204B1 (en) 2020-04-29 2021-03-30 Nanopharmaceuticals Llc Composition of scalable thyrointegrin antagonists with improved blood brain barrier penetration and retention into brain tumors
US11723888B2 (en) 2021-12-09 2023-08-15 Nanopharmaceuticals Llc Polymer conjugated thyrointegrin antagonists

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5422090A (en) 1984-08-13 1995-06-06 Biotechnology Australia, Pty., Ltd. Human PAI-2
IL81879A (en) 1986-03-13 1994-07-31 Biotech Australia Pty Ltd Purification of minactivin for homogeneity, production of minactivin as recombinant techniques, and uses of homogeneous or recombinant minactivin
US5073626A (en) 1988-11-09 1991-12-17 Monsanto Company Affinity purification of plasminogen activator inhibitor I using a modified urokinase
DE69033653T2 (de) 1989-04-07 2001-06-07 Cancerforskningsfonden Af 1989 (Fonden Til Fremme Af Eksperimental Cancerforskning), Kopenhagen Plasminogen-aktivator-rezeptor vom urokinasetyp
DK182289D0 (da) * 1989-04-14 1989-04-14 Francesco Blasi Modifikation af proteiner
WO1991002057A1 (en) 1989-08-09 1991-02-21 Delta Biotechnology Limited Polypeptide production in fungi
GB8919803D0 (en) 1989-09-01 1989-10-18 Ciba Geigy Pharmaceutical compositions
ES2106772T3 (es) 1989-12-20 1997-11-16 Biotech Australia Pty Ltd Variantes de pai-2.
GB2246779B (en) 1990-08-03 1994-08-17 Delta Biotechnology Ltd Tumour-associated protease inhibitors targeted to tumour cells
US5470970A (en) 1991-02-28 1995-11-28 Dana-Farber Cancer Institute, Inc. Maspin, a serpin with tumor suppresing activity
US5382514A (en) * 1992-03-31 1995-01-17 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services In vivo angiogenesis assay
AU4394293A (en) 1992-05-28 1993-12-30 University Of Toledo, The Delivery of a cytotoxic compound to a cancer cell using a pathway of plasminogen activator material
EP0673384A4 (de) * 1992-12-10 1996-10-09 Univ Minnesota Polypeptide nützlich in der behandlung von entzündlichen erkrankungen.
KR960702846A (ko) * 1993-05-28 1996-05-23 로버트 피. 블랙버언 우로키나제 리셉터 활성의 펩티드 저해인자(peptide inhbitors of urokinase receptor activity)
EP0802983B1 (de) 1993-06-01 2003-05-02 Chiron Corporation Expression von inhibitoren vom plasminogenaktivator vom urokinasetyp
DK85193D0 (da) 1993-07-16 1993-07-16 Cancerforskningsfondet Af 1989 Suppression of inhibitors
IT1271684B (it) 1994-07-22 1997-06-04 Consiglio Nazionale Ricerche Oligonucleotidi antisenso complementari all'rna messaggero del recettore umano della urochinasi
WO1997005257A1 (en) * 1995-07-31 1997-02-13 Chiron Corporation Peptide analog inhibitors of urokinase receptor activity
US6509445B1 (en) * 1996-01-08 2003-01-21 Nissin Food Products Co., Ltd. Cancerous metastasis inhibitor

Also Published As

Publication number Publication date
CY1107051T1 (el) 2012-10-24
AU752205B2 (en) 2002-09-12
EP0950096A1 (de) 1999-10-20
US20030027768A1 (en) 2003-02-06
CA2269772A1 (en) 1999-02-04
US7807621B2 (en) 2010-10-05
DE69836199D1 (de) 2006-11-30
DK0950096T3 (da) 2007-02-19
US5994309A (en) 1999-11-30
EP0950096B1 (de) 2006-10-18
US6696416B1 (en) 2004-02-24
AU8590098A (en) 1999-02-16
US20110065640A1 (en) 2011-03-17
DE69836199T2 (de) 2007-09-13
WO1999005263A1 (en) 1999-02-04
US20090143303A1 (en) 2009-06-04
PT950096E (pt) 2007-02-28
ES2275309T3 (es) 2007-06-01
US8110543B2 (en) 2012-02-07

Similar Documents

Publication Publication Date Title
DE69836199D1 (de) Anti-invasive and anti-angiogene urokinase fragmente und deren verwendung
JP5559087B2 (ja) 胃腸障害の治療のための方法および組成物
MY128654A (en) Liquid pharmaceutical composition containing an erythropoietin derivative
KR970707141A (ko) 종양 괴사 인자-감마(Tumor necrosis factor-gamma)
JP2008501310A6 (ja) 胃腸障害の治療のための方法および組成物
WO1997030085B1 (en) Troponin subunits and fragments useful as angiogenesis inhibitors
ATE362766T1 (de) Apolipoprotein a-i agonisten sowie deren verwendung zur behandlung dislipidemischer erkrankungen
MA26458A1 (fr) Nouveaux derives cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent.
RU98123834A (ru) СПОСОБЫ И КОМПОЗИЦИИ, ИСПОЛЬЗУЕМЫЕ ДЛЯ ИНГИБИРОВАНИЯ αvβ5ОПОСРЕДОВАННОГО АНГИОГЕНЕЗА
JP5372096B2 (ja) 新規な抗腫瘍化合物
BRPI0721259A2 (pt) composto, composiÇço farmacÊutica, uso de composto, e, processo para a fabricaÇço de composto
CN109248310B (zh) 利用θ-防御素的炎性蛋白酶的阻断
KR920004418A (ko) 브래디키닌 길항제
RU95111308A (ru) Производные 2-амино-4-фенил-4-оксомасляной кислоты, способы получения, фармацевтическая композиция
DE60008399D1 (de) Carbonsäuren und acylsulfonamide, solche verbindungen enthaltende zubereitungen und behandlungsmethoden
KR20000005210A (ko) 고리형 부착 억제제_
MXPA05005545A (es) Peptidos que se dirigen a celulas tomurales y endoteliales, composiciones y usos de los mismos.
EP1194531B1 (de) Zyklische peptidomimetische urokinaserezeptorantagonisten
EP1812035A4 (de) Peptid mit antitumoraler wirkung
WO1998046632A2 (de) Inhibitoren für den urokinaserezeptor
Cai et al. Recent developments in targeting bromodomain and extra terminal domain proteins for cancer therapeutics
SE9700244D0 (sv) Novel antibacterial protein
EP0670165B1 (de) Verwendung der Seminalribonuklease als antimetastatische Verbindung
GR3031254T3 (en) Novel derivatives of peptides therapeutically active in the cascade sequence for blood coagulation, process for their preparation and pharmaceutical compositions containing same
US20210238229A1 (en) Peptide for disease treatment

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0950096

Country of ref document: EP